Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

In the second study in Nature, researchers from Canada and Finland used microarrays—chips dotted with pieces of target DNA—to analyze another type of genetic mutation in iPS cells: small deletions or duplications of DNA known as structural variations. They found that iPS cells had more of these variations than either skin cells or embryonic stem cells did early in the reprogramming process but that cells bearing abnormalities quickly died off as the population continued to grow.

Researchers say that more research is needed to understand what the findings mean for future use of these cells in therapies. “The big question is which of these changes really matter,” says Jeanne Loring, director of the Center for Regenerative Medicine at Scripps Research Institute. “We need to figure out which are relevant and which are just noise.” Loring has published results similar to the second study this year.

“For some type of genetic changes—mutations in cancer-linked genes, for example—we clearly would not want to use cells in patients,” says Martin Pera, director of the Broad Center for Regenerative Medicine at the University of Southern California, who wrote a commentary accompanying the publication in Nature.  “But for the vast range of changes, we don’t really understand functional significance.” As is the case in many genomics studies, “the ability to collect in-depth genetic information has outstripped our ability to interpret it,” he says. “That’s the real challenge going forward.”

Part of the problem is that scientists know little about the mechanisms underlying reprogramming. “We can’t yet identify what particular aspect of the reprogramming process or cell culture is responsible for engendering these changes,” says Pera. “If we want to fix this, we need to understand what aspect of the process is critical.”

4 comments. Share your thoughts »

Credit: James Thomson, University of Wisconsin-Madison

Tagged: Biomedicine, stem cells, genome, sequencing, iPS cells, embryonic stem cells, reprogramming, mutations

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me